Atezolizumab and nabpaclitaxel prolong progressionfree survival for patients with metastatic triplenegative breast cancer the IMpassion130 trial

Atezolizumab and nab-paclitaxel prolong progression-free survival for patients with metastatic triple-negative breast cancer: the IMpassion130 trial

1. This randomized controlled trial of women with metastatic triple-negative breast cancer reports that patients who were received atezolizumab with nab-paclitaxel had longer periods of progression-free survival compared to patients who received placebo plus nab-paclitaxel therapy. 2. Rates of adverse events were comparable in both study groups, however it was noted that the incidence of […]

More From BioPortfolio on "Atezolizumab and nab-paclitaxel prolong progression-free survival for patients with metastatic triple-negative breast cancer: the IMpassion130 trial"